Back to top
more

Zimmer Biomet (ZBH)

(Real Time Quote from BATS)

$116.04 USD

116.04
600,097

+0.58 (0.50%)

Updated Sep 3, 2024 03:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.

Zimmer Biomet (ZBH) Is Up 0.07% in One Week: What You Should Know

by Zacks Equity Research

Does Zimmer Biomet (ZBH) have what it takes to be a top stock pick for momentum investors? Let's find out.

ZBH or MDT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ZBH vs. MDT: Which Stock Is the Better Value Option?

Zimmer Biomet (ZBH) Q4 Earnings Top Estimates, Margins Grow

by Zacks Equity Research

Zimmer Biomet (ZBH) benefits from strong sales growth across all geographies as well as segmental strengths at CER.

Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 1.77% and 0.92%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Cardinal Health's (CAH) Q2 Earnings?

by Zacks Equity Research

Cardinal Health (CAH) fiscal second-quarter earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.

Cerner (CERN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to have aided Cerner's (CERN) Q4 earnings. However, contraction in gross margin is likely to have been a dampener.

What's in the Cards for Zimmer Biomet (ZBH) in Q4 Earnings?

by Zacks Equity Research

Gains from developments in business segments are likely to get reflected in Zimmer Biomet's (ZBH) revenue results for the fourth quarter and 2019.

Zimmer Biomet (ZBH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Baxter (BAX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Higher revenues, solid product portfolio and strong performance across six global business units are likely to have benefited Baxter's (BAX) Q4 earnings.

What's in Store for AmerisourceBergen (ABC) in Q1 Earnings?

by Zacks Equity Research

AmerisourceBergen's (ABC) Q1 earnings are likely to reflect the better-than-expected performance at Pharmaceutical Distribution and higher revenues.

Zimmer (ZBH) Stock Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent developments.

Zimmer Biomet Rides on Product Launches Despite Pricing Woes

by Zacks Equity Research

Zimmer Biomet's (ZBH) execution of its priority agenda including quality remediation, supply recovery efforts and product introductions looks impressive.

Stryker (SYK) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine are likely to have contributed to Stryker's (SYK) Q4 earnings.

PerkinElmer (PKI) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Top-line growth and robust performance at Diagnostics segment are likely to have aided PerkinElmer's (PKI) Q4 earnings. However, forex is likely to have remained a woe.

What's in the Cards for Intuitive Surgical (ISRG) Q4 Earnings?

by Zacks Equity Research

Better-than-expected performance at Instruments & Accessories segment and da Vince procedure growth are likely to have benefited Intuitive Surgical's (ISRG) Q4 earnings.

Will Zimmer (ZBH) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Here's Why You Should Hold on to Zimmer (ZBH) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Zimmer (ZBH) on its stellar segmental performance in Q3.

Zimmer Biomet Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Zimmer Biomet (ZBH) is optimistic about maintaining growth momentum on several recent positive developments.

Zimmer Biomet Focuses on Priority Areas Despite Pricing Woes

by Zacks Equity Research

Zimmer Biomet (ZBH) is executing well within its priority areas like quality remediation, supply recovery efforts and product rollouts.

Zimmer (ZBH) Up 3.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zimmer (ZBH) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent positive developments.

Zimmer (ZBH) Scales 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Zimmer (ZBH) is likely to maintain the current high on a number of favorable factors.

Zimmer Biomet (ZBH) Q3 Earnings Top, Operating Margin Falls

by Zacks Equity Research

Zimmer Biomet (ZBH) gains from strong sales growth across all geographies and most operating segments in Q3.

Zimmer Biomet (ZBH) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 0.57% and 1.02%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products' Earnings Roster for Nov 5: BDX, ZBH & More

by Urmimala Biswas

Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.